12 hrs ago | Seeking Alpha
Diabetes And Oncology Might Cushion Eli Lilly's Fall Off A Patent Cliff
Eli Lilly and Company is heading straight for a patent cliff. Zyprexa lost patent protection in most major markets in 2011.
16 hrs ago | Insider Monkey
This Metric Says You Are Smart to Sell Bristol Myers Squibb Co.
BMY has experienced a decrease in support from the world's most elite money managers recently.
Yesterday | Free Republic
On the morning of Aug. 18, 2004, Dinesh Thakur hurried to a hastily arranged meeting with his boss at the gleaming offices of Ranbaxy Laboratories in Gurgaon, India, 20 miles south of New Delhi.
Peregrine Pharmaceuticals, The Little Biotech With The Golden Goose Of Immunotherapy
The annual conference of The American Society of Clinical Oncology is currently less than a few days away, and what is the buzz for this year's conference? Immunotherapy is the buzz word for this year's conference.
Amgen, Inc. (AMGN), Bristol Myers Squibb Co. (BMY): Can Financial...
A few years ago, Andrew W. Lo from the MIT Sloan School of Management gave a lengthy talk at a meet-and-greet for prospective students of the Master of Finance program.
Wall Street has a Wile E. Coyote moment
WASHINGTON, May 23, 2013 The mood is grim on Wall Street this morning after yesterday's double whammy.
Free Research Reports on AFOP, BMY, LO and ZLC Issued by the Bedford Report
As a leading provider of free in depth reports and timely market updates, Bedford is an essential resource for hundreds of thousands of investors across the country.
Top US stock recommendations of the day: ADVANCED MICRO DEVICES: Jefferies & Co reiterates BUY rating.
Movers & Shakers: Wednesday's movers: Drug makers lead S&P 500
Pharmaceutical names dominated the S&P 500's leaderboard with Bristol-Myers Squibb Co.
Immune system cancer drugs tipped to be a $35 bln market
A new wave of medicines that tap the power of the immune system to fight cancer could become the biggest drug class in history, with potential sales of $35 billion a year.
Bristol-Myers Squibb Company is Fined for Monkey Deaths, but Will $2,600 Matter?
Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today! In what is apparently an unusual move, the US Department of Agriculture earlier this year fined Bristol-Myers Squibb for violating the Animal Welfare Act after the deaths of two monkeys in its laboratories.
Teva Bets on Reformulating Drugs as Investors Say - Show Me'
Teva Pharmaceutical Industries Ltd., which just two years ago was analysts' highest-rated stock among the world's 20 biggest drugmakers, is struggling to convince investors that a key part of its strategy will revive growth.
Bloomsbury Publishing Receives "Buy" Rating from Investec
's stock had its "buy" rating restated by equities researchers at Investec in a report issued on Tuesday, StocKRatingsNetwork.com reports.
Bristol Myers Squibb And The New Wave Of Cancer Drugs
Even with the best cancer drugs, doctors are forced to switch from one therapy to the next as the tumors rapidly develop resistance.
FTSE 100 movers: RBS makes strong gains on Numis note
Royal Bank of Scotland was in the lead after Numis raised its target price from 308p to 410p, while upgrading the stock to buy.
Chinese pharma companies look West
Zhejiang Hisun Pharmaceutical Co's pavilion at a fair in Beijing. By setting up a joint venture with US-based Pfizer Inc in September, Hisun made a breakthrough in China's pharmaceutical industry by taking a controlling stake in the JV with Pfizer, the world's largest drug-maker by sales.
Bristol-Myers Squibb drug study showed effectiveness against advanced melanoma cancer
Two drugs from Bristol-Myers Squibb Co. shrank tumors in as many as half of patients with advanced melanoma, according to early research that may pave the way for cocktails that trigger the immune system to destroy cancer.
Bristol-Myers Drug Cocktail Quells Melanoma Tumors, Study Finds
Two drugs from Bristol-Myers Squibb Co. shrank tumors in as many as half of patients with advanced melanoma, according to early research that may pave the way for cocktails that trigger the immune system to destroy cancer.
Bristol-Myers shares jump ahead of melanoma trial data
Bristol-Myers shares were up 5.1 percent at $44.35 shortly before the close on Wednesday, in their busiest day of trading since August.
Bristol-Myers Squibb: The Caped Crusaders
Bristol-Myers Squibb's Joseph Campisi and Demetrios Kyonieus were virtually inseparable for eight months in 2012 while they negotiated an M&A deal that was large and complex.